Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Navy General Hospital, Beijing | OTHER |
| Air Force Military Medical University, China | OTHER |
| Beijing Tongren Hospital | OTHER |
| Beijing Friendship Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Most studies of bloating have focused on functional factors, while data on organic abdominal distention are rare, and studies that combine small intestine bacterial overgrowth and/or oral cecum transit time abnormalities are more urgent to explore. On this basis, patients with functional abdominal distension complicated with small intestine bacterial overgrowth were divided according to whether there was abnormal oral cecum transit time, and given the same treatment plan. The relief effect of abdominal distension, small intestine bacterial overgrowth turning negative and oral cecum transit time recovery were observed, so as to further clarify the cause of abdominal distension patients.
Part 1 Clinical characteristics of small intestinal bacterial overgrowth in patients with abdominal distension of different etiologies The clinical characteristics of small intestine bacterial overgrowth and oral cecum transit time in patients with abdominal distention of different etiology (organic and functional) were studied to lay a foundation for further exploration of treatment of functional abdominal distention.
Part 2 Efficacy observation of functional abdominal distention combined with small intestine bacterial overgrowth To observe the effect of antibiotics on abdominal distension in patients with functional abdominal distension complicated with small intestine bacterial overgrowth, and observe the effect of rifaximin on small intestine bacterial overgrowth and oral cecum transit time, so as to provide new ideas for the diagnosis and treatment of abdominal distension patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sham Comparator(Normal oral cecum transit time) | Sham Comparator | Normal oral cecum transit time +functional abdominal distention +small intestinal bacterial overgrowth.Rifaximin (0.2g/ time, 4 times/day) was discontinued after 14 days of treatment. |
|
| Experimental(Abnormal oral cecum transit time) | Experimental | Abnormal oral cecum transit time +functional abdominal distention +small intestinal bacterial overgrowth.Rifaximin (0.2g/ time, 4 times/day) was discontinued after 14 days of treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rifaximin | Drug | Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal. |
| Measure | Description | Time Frame |
|---|---|---|
| Part 1 Positive rate of small intestinal bacterial overgrowth | Positive rate of small intestinal bacterial overgrowth in organic and functional abdominal distension | 1 day |
| Part 1 Abnormal rate of oral cecum transit time | Abnormal rate of oral cecum transit time in organic and functional abdominal distension | 1 day |
| Part 2 Effective rate of abdominal distension | Total effective rate (%) = Obvious effective rate (%) + Effective rate (%)
| 2 weeks |
| Part 2 Negative conversion rate of small intestinal bacterial overgrowth and oral cecum transit time |
| 2 weeks |
Not provided
Not provided
Inclusion criteria:
Part 1 Clinical characteristics of small intestinal bacterial overgrowth in patients with abdominal distension of different etiologies
Part 2 Efficacy observation of functional abdominal distention combined with small intestine bacterial overgrowth
Exclusion criteria:
Part 1 Clinical characteristics of small intestinal bacterial overgrowth in patients with abdominal distension of different etiologies
Part 2 Efficacy observation of functional abdominal distention combined with small intestine bacterial overgrowth
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jing-Nan Li, MD,Ph.D | Contact | 13601235229 | Jing-NanLilijn2008@126.com |
| Name | Affiliation | Role |
|---|---|---|
| Jing-Nan Li, MD,Ph.D | Peking Union Medical College Hospital | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D000078262 | Rifaximin |
| ID | Term |
|---|---|
| D012294 | Rifamycins |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| OTHER |
| Beijing Chao Yang Hospital | OTHER |
| Beijing Tiantan Hospital | OTHER |
| The Luhe Teaching Hospital of the Capital Medical University | OTHER |
| China-Japan Friendship Hospital | OTHER |
| Beijing Aerospace General Hospital | OTHER |
| Beijing Jishuitan Hospital | OTHER |
| Peking University Third Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| D047029 | Lactams, Macrocyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |